首页> 外文OA文献 >Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

【2h】

Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

机译：尽管甲氨蝶呤治疗早在第2周就出现了反应，静脉戈利木单抗在活动性类风湿性关节炎患者中仍然有效：第3阶段，随机，多中心，双盲，安慰剂对照的GO-FURTHER试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Weinblatt, Michael E; Bingham, Clifton O; Mendelsohn, Alan M; Kim, Lilianne; Mack, Michael; Baker, Daniel; Westhovens, Rene;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: Results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial [J] . WeinblattM.E., BinghamIIIC.O., MendelsohnA.M., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2013,第3期

机译：尽管甲氨蝶呤治疗早在第2周就出现了反应，静脉戈利木单抗在活动性类风湿性关节炎患者中仍然有效：第3阶段，随机，多中心，双盲，安慰剂对照的GO-FURTHER试验的结果
2. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. [J] . Michael E Weinblatt, Rene Westhovens, Alan M Mendelsohn, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第12期

机译：尽管已接受甲氨蝶呤治疗，但活动性类风湿关节炎患者在接受类风湿性关节炎治疗时，影像学获益和维持静脉内golimumab治疗的临床益处：长达1年的3期，随机，多中心，双盲，安慰剂对照的GO-FURTHER试验结果。
3. Erratum: Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [J] . li id=au1Paul Emery li id=au2Roy M. Fleischmann li id=au3Larry W. Moreland li id=au4Elizabeth C. Hsia li id=au5Ingrid Strusberg li id=au6Patrick Durez li id=au7Peter Nash li id=au8Eric Jason B. Amante li id=au9Melvin Churchill li id=au10Won Park li id=au11Bernardo Antonio Pons-Estel li id=au12Mittie K. Doyle li id=au13Sudha Visvanathan li id=au14Weichun Xu li id=au15Mahboob U. Rahman Arthritis & Rheumatism . 2010,第9期

机译：勘误：Golimumab，一种人类抗肿瘤坏死因子单克隆抗体，每隔四周皮下注射一次未接受甲氨蝶呤的活动性类风湿性关节炎患者：三期，多中心，随机，双盲，安慰剂治疗二十三周的结果氨甲蝶呤前戈利木单抗作为早期治疗类风湿关节炎的一线治疗的对照研究
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Extended report: Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3 randomised multicentre double blind placebo controlled GO-FURTHER trial [O] . Michael E Weinblatt, Rene Westhovens, Alan M Mendelsohn, -1

机译：扩展报告：尽管接受甲氨蝶呤治疗但活动性类风湿性关节炎患者在接受类风湿性关节炎治疗时影像学获益和静脉内戈利木单抗治疗的维持性：长达3年的1年随机多中心双盲安慰剂对照的GO-FURTHER试验
7. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis : twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. [O] . Emery, Paul, Fleischmann, Roy M, Moreland, Larry W, 2009

机译：Golimumab是一种人类抗肿瘤坏死因子α单克隆抗体，每4周一次向未接受甲氨蝶呤治疗的活动性类风湿关节炎患者皮下注射：III期，多中心，随机，双盲，安慰剂对照的24周结果甲氨蝶呤前戈利木单抗作为早期治疗类风湿关节炎的一线治疗的研究。

Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

著录项

相似文献

相关主题

期刊订阅